Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2021		Dec. 31, 2020		Dec. 31, 2019
Revenues:
Products, net	$ 612,401		$ 455,865		$ 380,833
Type of Revenue [Extensible List]	us-gaap:ProductMember		us-gaap:ProductMember		us-gaap:ProductMember
Collaboration and other	$ 89,486		$ 84,234		$ 0
Total revenues	701,887		540,099		380,833
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)	97,049		63,382		56,586
Research and development	771,182		722,343		560,909
Selling, general and administrative	282,660		317,875		284,812
Settlement and license charges	10,000		0		10,000
Amortization of in-licensed rights	706		662		849
Acquired in-process research and development	0		0		173,240
Total cost and expenses	1,161,597		1,104,262		1,086,396
Operating loss	(459,710)		(564,163)		(705,563)
Other income (loss):
Gain from sale of Priority Review Voucher	102,000		108,069
Gain (loss) on contingent consideration, net	7,200	[1]	(45,000)	[1]
Other expense, net	(68,438)		(51,971)		(8,317)
Total other income (loss)	40,762		11,098		(8,317)
Loss before income tax (benefit) expense	(418,948)		(553,065)		(713,880)
Income tax (benefit) expense	(168)		1,063		1,195
Net loss	(418,780)		(554,128)		(715,075)
Other comprehensive loss:
Unrealized (losses) gains on investments, net of tax	(23)		(47)		149
Total other comprehensive (loss) income	(23)		(47)		149
Comprehensive loss	$ (418,803)		$ (554,175)		$ (714,926)
Net loss per share — basic and diluted	$ (5.15)		$ (7.11)		$ (9.71)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share	81,262		77,956		73,615

[1] The gain (loss) on contingent consideration, net is related to the fair value adjustment of the regulatory-related contingent payments that are accounted for as derivatives. Please see Note 5. Fair Value Measurements for further details.